10-Q: Arbutus Biopharma Reports Q2 2024 Results, Streamlines Operations to Extend Cash Runway

Arbutus Biopharma announced its second quarter 2024 financial results and a strategic restructuring to focus on key clinical programs and extend its cash runway into the fourth quarter of 2026.

Summary

• Arbutus Biopharma reported a net loss of $19.8 million for the three months ended June 30, 2024, and a net loss of $37.7 million for the six months ended June 30, 2024.
• The company's total revenue was $1.7 million for the quarter and $3.3 million for the six-month period, primarily from collaborations and licenses, and non-cash royalty revenue.
• Operating expenses totaled $23.3 million for the quarter and $44.2 million for the six-month period, with research and development accounting for the largest portion.
• As of June 30, 2024, Arbutus had $148.5 million in cash, cash equivalents, and marketable securities.
• The company has implemented a 40% workforce reduction and ceased discovery efforts to focus on advancing imdusiran and AB-101, which is expected to result in a one-time restructuring charge of $3.0 to $4.0 million in Q3 2024.
• Arbutus now anticipates its current cash resources will fund operations into the fourth quarter of 2026.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has extended its cash runway and is focusing on key programs, the significant workforce reduction, discontinuation of a clinical trial, and revenue decline are concerning. The ongoing litigation and potential for future royalties are positive, but the overall sentiment is cautiously negative.

Positives

• The company has sufficient cash resources to fund operations into the fourth quarter of 2026.
• The company is focusing on its lead HBV product candidates, imdusiran and AB-101.
• The company has achieved statistical significance in lowering HBsAg levels in the IM-PROVE II clinical trial.
• The company has seen some patients achieve undetectable HBsAg in the IM-PROVE I trial.
• The company has a strong intellectual property portfolio, including ongoing litigation against Moderna and Pfizer/BioNTech.

Negatives

• The company reported a net loss of $19.8 million for the quarter and $37.7 million for the six-month period.
• Total revenue decreased by $2.9 million for the quarter and $8.1 million for the six-month period compared to 2023.
• The company is implementing a 40% workforce reduction.
• The company has ceased all discovery efforts and discontinued the IM-PROVE III clinical trial.
• The company's lawsuit against Moderna has been delayed until September 2025.

Risks

• The company's success is dependent on obtaining regulatory approvals for its products.
• The company's research and development activities are dependent on its ability to secure adequate financing.
• The company's ongoing litigation against Moderna and Pfizer/BioNTech is subject to uncertainty.
• The company's future revenue is dependent on the success of its collaborations and licensing agreements.
• The company's clinical trials may not be successful, and its product candidates may not be approved.

Future Outlook

Arbutus expects its current cash, cash equivalents, and investments in marketable securities will be sufficient to fund operations into the fourth quarter of 2026. The company anticipates a net cash burn between $63 million and $67 million in 2024.

Management Comments

• The company is streamlining the organization to focus on advancing the clinical development of imdusiran and AB-101.
• The company believes that a combination of compounds that can suppress HBV DNA replication and HBsAg expression as well as boost patients HBV-specific immune response could address the most important elements to achieving a functional cure.
• The company is positioning imdusiran as a potential cornerstone therapeutic in combination with AB-101 or other agents with potentially complementary mechanisms of action.

Industry Context

Arbutus is operating in the competitive biopharmaceutical industry, focusing on developing a functional cure for chronic hepatitis B virus (cHBV) infection. The company's approach involves combining therapies that suppress the virus and boost the immune response, which is a common strategy in the field. The company is also involved in intellectual property litigation related to its LNP technology, which is a key area of focus in the broader RNA therapeutics space.

Comparison to Industry Standards

• Arbutus's approach to HBV treatment, combining RNAi therapeutics with immune modulators, aligns with current industry trends in developing combination therapies for chronic viral infections.
• The company's focus on achieving a functional cure, defined as undetectable HBV DNA and HBsAg levels six months after treatment discontinuation, is a common goal in the HBV therapeutic space.
• The company's clinical trial results, particularly the HBsAg reductions observed with imdusiran, are comparable to those reported by other companies developing similar therapies.
• The company's litigation against Moderna and Pfizer/BioNTech highlights the importance of intellectual property in the biopharmaceutical industry, similar to other high-profile patent disputes in the sector.
• The company's restructuring and workforce reduction are not uncommon in the biotech industry, especially for companies in the clinical stage facing financial constraints, similar to companies such as Vir Biotechnology and Dicerna Pharmaceuticals.

Legal Proceedings

• Arbutus and Genevant are involved in ongoing patent infringement litigation against Moderna and Pfizer/BioNTech.
• The claim construction hearing in the Moderna lawsuit occurred on February 8, 2024, and the court issued its opinion on April 3, 2024.
• The start of the trial in the Moderna lawsuit has been rescheduled to September 24, 2025, pending court approval.
• The lawsuit against Pfizer/BioNTech is ongoing, with document and written discovery underway.
• Acuitas voluntarily dismissed its complaint in the Southern District of New York and refiled a virtually identical complaint in the District Court of New Jersey, which was subsequently dismissed on May 20, 2024.

Stakeholder Impact

• Shareholders may be concerned about the company's net losses and workforce reduction, but may be encouraged by the extended cash runway and focus on key programs.
• Employees are significantly impacted by the 40% workforce reduction.
• Customers and partners may be affected by the company's strategic shift and discontinuation of certain programs.
• Creditors are not directly impacted as the company has no outstanding debt.

Next Steps

• The company will continue to advance the clinical development of imdusiran and AB-101.
• The company will report preliminary end-of-treatment data from the additional cohort of the IM-PROVE II clinical trial in the second half of 2024.
• The company will report preliminary data from Part 2 of the AB-101-001 clinical trial in the second half of 2024.
• The company will continue to pursue its intellectual property litigation against Moderna and Pfizer/BioNTech.

Key Dates

Keywords

Arbutus Biopharma, Hepatitis B, imdusiran, AB-101, RNAi, PD-L1 inhibitor, clinical trials, LNP technology, Moderna, Pfizer, BioNTech, ONPATTRO, royalty, restructuring, cash runway